MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- CADILA HEALTHCARE - AUROBINDO PHARMA
CADILA HEALTHCARE vs AUROBINDO PHARMA - Comparison Results
CADILA HEALTHCARE Change
Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
AUROBINDO PHARMA 
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
Current Valuations
| CADILA HEALTHCARE | AUROBINDO PHARMA | CADILA HEALTHCARE/ AUROBINDO PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 18.0 | 9.8 | 182.6% | View Chart |
| P/BV | x | 2.4 | 1.8 | 132.3% | View Chart |
| Dividend Yield | % | 1.4 | 0.6 | 247.5% |
Financials
 CADILA HEALTHCARE  AUROBINDO PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CADILA HEALTHCARE Mar-19 |
AUROBINDO PHARMA Mar-19 |
CADILA HEALTHCARE/ AUROBINDO PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 432 | 830 | 52.1% | |
| Low | Rs | 306 | 527 | 58.1% | |
| Sales per share (Unadj.) | Rs | 128.6 | 333.9 | 38.5% | |
| Earnings per share (Unadj.) | Rs | 18.5 | 40.4 | 46.0% | |
| Cash flow per share (Unadj.) | Rs | 24.4 | 51.8 | 47.1% | |
| Dividends per share (Unadj.) | Rs | 3.50 | 2.50 | 140.0% | |
| Dividend yield (eoy) | % | 0.9 | 0.4 | 257.2% | |
| Book value per share (Unadj.) | Rs | 101.5 | 237.1 | 42.8% | |
| Shares outstanding (eoy) | m | 1,023.74 | 585.91 | 174.7% | |
| Bonus/Rights/Conversions | - | ESOP | - | ||
| Price / Sales ratio | x | 2.9 | 2.0 | 141.3% | |
| Avg P/E ratio | x | 19.9 | 16.8 | 118.5% | |
| P/CF ratio (eoy) | x | 15.1 | 13.1 | 115.5% | |
| Price / Book Value ratio | x | 3.6 | 2.9 | 127.2% | |
| Dividend payout | % | 18.9 | 6.2 | 304.6% | |
| Avg Mkt Cap | Rs m | 378,170 | 397,569 | 95.1% | |
| No. of employees | `000 | 12.4 | 17.9 | 69.7% | |
| Total wages/salary | Rs m | 21,241 | 25,849 | 82.2% | |
| Avg. sales/employee | Rs Th | 10,585.0 | 10,956.9 | 96.6% | |
| Avg. wages/employee | Rs Th | 1,707.8 | 1,447.7 | 118.0% | |
| Avg. net profit/employee | Rs Th | 1,526.5 | 1,324.3 | 115.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 131,656 | 195,636 | 67.3% | |
| Other income | Rs m | 2,011 | 1,553 | 129.5% | |
| Total revenues | Rs m | 133,667 | 197,189 | 67.8% | |
| Gross profit | Rs m | 29,731 | 39,519 | 75.2% | |
| Depreciation | Rs m | 5,986 | 6,680 | 89.6% | |
| Interest | Rs m | 1,935 | 2,626 | 73.7% | |
| Profit before tax | Rs m | 23,821 | 31,767 | 75.0% | |
| Minority Interest | Rs m | 469 | 27 | 1,737.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -881 | 0.0% | |
| Tax | Rs m | 5,303 | 7,269 | 73.0% | |
| Profit after tax | Rs m | 18,987 | 23,645 | 80.3% | |
| Gross profit margin | % | 22.6 | 20.2 | 111.8% | |
| Effective tax rate | % | 22.3 | 22.9 | 97.3% | |
| Net profit margin | % | 14.4 | 12.1 | 119.3% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 84,981 | 153,645 | 55.3% | |
| Current liabilities | Rs m | 73,425 | 120,429 | 61.0% | |
| Net working cap to sales | % | 8.8 | 17.0 | 51.7% | |
| Current ratio | x | 1.2 | 1.3 | 90.7% | |
| Inventory Days | Days | 75 | 135 | 55.1% | |
| Debtors Days | Days | 110 | 64 | 172.0% | |
| Net fixed assets | Rs m | 133,493 | 103,909 | 128.5% | |
| Share capital | Rs m | 1,024 | 586 | 174.8% | |
| "Free" reserves | Rs m | 102,839 | 138,322 | 74.3% | |
| Net worth | Rs m | 103,863 | 138,908 | 74.8% | |
| Long term debt | Rs m | 39,497 | 1,800 | 2,194.9% | |
| Total assets | Rs m | 234,831 | 264,544 | 88.8% | |
| Interest coverage | x | 13.3 | 13.1 | 101.6% | |
| Debt to equity ratio | x | 0.4 | 0 | 2,935.5% | |
| Sales to assets ratio | x | 0.6 | 0.7 | 75.8% | |
| Return on assets | % | 8.9 | 9.9 | 89.7% | |
| Return on equity | % | 18.3 | 17.0 | 107.4% | |
| Return on capital | % | 18.3 | 23.8 | 76.7% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 48,404 | 97,316 | 49.7% | |
| Fx outflow | Rs m | 11,593 | 40,589 | 28.6% | |
| Net fx | Rs m | 36,811 | 56,727 | 64.9% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 28,823 | 16,220 | 177.7% | |
| From Investments | Rs m | -57,387 | -28,768 | 199.5% | |
| From Financial Activity | Rs m | 18,846 | 19,191 | 98.2% | |
| Net Cashflow | Rs m | -7,105 | 6,656 | -106.7% | |
Share Holding
| Indian Promoters | % | 74.8 | 54.1 | 138.3% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 8.3 | 8.0 | 104.4% | |
| FIIs | % | 5.9 | 27.7 | 21.3% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 11.0 | 10.2 | 107.8% | |
| Shareholders | 44,069 | 69,601 | 63.3% | ||
| Pledged promoter(s) holding | % | 0.0 | 8.6 | - |
Compare CADILA HEALTHCARE With: DR. DATSONS LABS DISHMAN PHARMA J.B.CHEMICALS JUBILANT LIFE SCIENCES DIVIS LABORATORIES
Compare CADILA HEALTHCARE With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 186 Points Higher; Energy and Power Stocks Witness Buying(Closing)
Indian share markets witnessed buying interest during closing hours today and ended their day on a positive note.
Related Views on News
AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)
Nov 15, 2019 | Updated on Nov 15, 2019For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)
Nov 15, 2019 | Updated on Nov 15, 2019For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Nov 6, 2019 | Updated on Nov 6, 2019Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
More Views on NewsMost Popular
Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)
Nov 7, 2019Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?
The Smartest Stock to Buy for 2020(Profit Hunter)
Nov 14, 2019Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...
Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)
Nov 8, 2019Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.
A Trade that Could Generate Profits for Decades
Nov 14, 2019India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...
The One Trade I'm Most Bullish on Now
Nov 12, 2019A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!
MoreCADILA HEALTHCARE SHARE PRICE
Nov 19, 2019 03:37 PM
TRACK CADILA HEALTHCARE
- Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CADILA HEALTHCARE
CADILA HEALTHCARE - DR. DATSONS LABS COMPARISON
COMPARE CADILA HEALTHCARE WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.